UPC Analytics
ENDE
Overview · Filed: Nov 10, 2023

CC_586764/2023

ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)

Parent infringement case:UPC_CFI_14/2023

RevocationCounter Claim for RevocationMunich CDCounter claim for revocationCase Closed
OverviewDecisionsReasoningCitationsDocumentsTimeline
Parties

Claimants

  • Regeneron Pharmaceuticals Inc.
Reps: Niels Hölder (Hoffmann Eitle); Agathe Michel-De Cazotte (Carpmaels & Ransford); Daniel Wise (Carpmaels & Ransford)

Respondents

Judges
  • Ulrike Voß
  • Andras Kupecz
  • Casper Struve
Patents
  • EP3666797
  • EP 3 666 797 B1
CPC codes: C07K2317/14, C07K2317/34, A61K39/395, A61K2039/505, A61K31/366, A61P3/06, A61K31/66, A61K31/22, A61P9/00, A61P7/00, A61P25/28, A61K2300/00…

Technology area: Biotech · Antibody

Sector: Biotechnology

Outcome
RevokedRevoked in full
Filed: Nov 10, 2023
First decided: Jul 16, 2024
Language: English

The patent EP 3 666 797 B1 was revoked in its entirety for all Contracting Member States in which revocation was requested. The Main Request and all 17 Auxiliary Requests were found to lack inventive step. The defendant (patent proprietor Amgen) was ordered to bear the claimant's legal costs, agreed at EUR 1.375 million.

Open on UPC Registry
Claims
At issueall
Revokedall
Notes: Patent EP 3 666 797 B1 revoked entirely; Main Request and all 17 Auxiliary Requests lacked inventive step.